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because in each case there is only one cutoff, it is not possible to
calculate an area under the curve (AUC) for ROC as one has only
one data point of corresponding sensitivity and specificity.
Further explanation is necessary. It would be worthwhile to
know how the p values for the differences between the AUCs were
obtained, as the p values seem very small (Table 2) for the
comparison between the two peak VO2 measures.
Additionally, it remains arguable whether the comparison to
Mancini’s cutoff is justified at all, as the cutoff was established in a
much sicker population, whereas the lean cutoff was specifically
designed for this population. Does selection of the optimal peak
VO2/weight cutoff change the predictive power of this variable?
Finally, we cannot consolidate the fact that the confidence interval
for the RR values in their Table 5 (1) encompasses 1.0, yet all p
values are highly significant.
The literature reviewed for the Osman et al. article appears
somewhat incomplete. Using the DEXA-scan, previous studies
have found that absolute peak VO2 (in ml/min) closely relates to
lean tissue mass in patients with congestive heart failure (CHF)
(5,6). That peak VO2/weight underestimates true exercise capacity
in obese patients with CHF (7) and overestimates it in cachectic
patients with CHF (8) has been suggested some years ago.
Finally, the investigators (1) conclude that peak VO2/lean
weight is the cardiopulmonary exercise parameter that provides
“the best risk stratification across the heterogeneous systolic heart
failure cohort.” The presented data do not justify this conclusion.
First, this is due to the above problems, but more importantly this
is because the VE/VCO2-slope (which is automatically provided by
the equipment the authors used) was ignored for all analyses. For
several years now the latter is known to be a strong prognosticator
(9,10) independently of peak VO2. In mild CHF, the VE/VCO2-
slope is even superior to peak VO2 in predicting prognosis (11).
Again, we believe the report by Osman et al. (1) examines an
important subject, and we agree that peak VO2/lean weight is
better than peak VO2/weight, but we also believe this message has
not been proven by these investigators, and that the points we
addressed above could have been beneficially optimized during the
review process.
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REPLY
We appreciate the opportunity to respond to the concerns raised by
Drs. Wensel and Anker, which in our opinion do not affect the
major results and conclusions of our study (1).
Of the 225 patients we studied, 170 (75%) reached anaerobic
threshold (mean VO2 at AT 12.28 6 3.97 ml/kg/min). Addition-
ally, at peak oxygen consumption, the mean respiratory exchange
ratio was 1.09 6 0.14, suggesting an adequate effort for the study
population.
The authors also point out the low mortality rate of our
population, and they compare our major event rate to that of the
smaller and sicker population studied by Mancini et al. (2).
Whereas 46% of our patients were in New York Heart Association
(NYHA) functional class III, 40% in class II and 14% in class I,
70% of the population in Mancini’s study were in NYHA
functional class III, and even 13% in class IV, with only 17% in
class II. In addition, owing to many years separating patient
selection for these two studies, there may be major differences in
overall medical management, including aggressive revasculariza-
tion of patients with ischemic cardiomyopathy, adequate use of
angiotensin-converting enzyme (ACE) inhibition (95% of our
patients) and an evolving mandated use of beta-blockers (31%),
which have likely reduced the morbidity and mortality for our
heart failure patients. However, we believe that our population is
representative of heart failure and cardiac transplant patients
currently presenting to large referral centers in the United States.
In addition, the relatively high percentages of women and, partic-
ularly, obese patients—with both groups having strong trends for
lower major event rates—further contribute to the low overall
event rate noted in our cohort.
The authors refer to several studies that corroborate the evidence
that lean body mass correlates better to peak oxygen consumption.
We regret not having mentioned Dr. Anker’s study using DEXA
scanning, an accurate technique but one that has not gained wide
practical acceptance. In our study we used a simple anthropometric
288 Letters to the Editor JACC Vol. 38, No. 1, 2001
July 2001:286–93
method, and despite the well-known limitation of this technique
that we discussed in our report, it still added considerably to the
prognostic value. The use of other validated methods of lean body
mass assessment, some more practical than others, may further
enhance the prognostic value of cardiopulmonary assessment.
We are quite familiar with the value of VE/VCO2 in the risk
stratification process in heart failure. We have previously shown
that patients with chronic heart failure (with peak VO2 ,14
ml/kg/min) showed a reduction in this ratio by less than 10% early
in exercise, as opposed to controls and to patients with milder
disease, who typically show more than 20% reduction (3). We
proposed that failure to reduce the VE/VCO2 early in exercise may
be used as a surrogate for low peak VO2 for patients who do not
achieve maximal exercise. Clark et al. (4) have shown that patients
with heart failure do not demonstrate a linear relationship between
VE/VCO2 and exercise time. Furthermore, these patients could be
classified into three patterns, which corresponded with increasing
severity of heart failure, as evidenced by peak VO2. Francis et al. (5)
also showed that, in their population, mean VE/VCO2 “slope” was
of strong and prognostic value, independent of peak VO2. In that
report, the investigators point out that the use of discrete cutoffs is
rather arbitrary when using continuous risk stratifiers with a wide
gradient of risk, and they may, in fact, be more specific to the
population from which they are derived.
In our population, although VE/VCO2 was significantly higher
in patients reaching an outcome compared to those who did not
(41.3 6 8.8 vs. 36 6 8, p , 0.001), this was not an independent
predictor of events in multivariate analysis, including peak VO2 or
lean peak VO2.
Several questions were raised regarding the statistical analysis in
our study. First, binormal receiver operator curve (ROC) analysis
was performed using PEPI software version 3.00 (USD, Stone
Mountain, Georgia). The appropriate cutoff point for our explan-
atory variable (lean peak VO2) was determined by ROC curve
analysis for the best trade-off between sensitivity and specificity.
The area under the curve (AUC) for the adjusted variable was
significantly higher (0.67 6 0.067 vs. 0.58 6 0.06; p 5 0.0001,
95% confidence interval for the difference of 20.1324 to
20.0432). In this analysis, the follow-up duration is not relevant.
In our Table 2, the AUC should have been clearly labeled as
referring to the use of the respective continuous variable, rather
than the dichotomized variables.
We then created, as shown in our revised Table 5, different Cox
models for each peak oxygen consumption variable, all including
age and etiology of congestive heart failure as a constant set of
covariates. Partial “Index-R” or the partial-correlation Index-R
statistic proposed by Harrel was used for comparing and ranking
the magnitude of the effect of the peak VO2-related variables
between the multivariate models (6). The p values refer to the
chi-square and Index-R value, which is shown in the revised Table
5, whereas the 95% CIs relate to the relative risk for each variable.
This was not significant for % predicted VO2 ,50. We apologize
for the confusion that this display may have caused.
Finally, we disagree with the concern about the “extensive
statistical analysis” with the low event rate in our population; the
ratio of events per variable studied in multivariate analysis was kept
around 10, which is conventionally acceptable (7). The fact
remains that peak oxygen consumption, particularly when adjusted
to lean body mass, remains a cornerstone of risk stratification in
heart failure that has not been superseded by any other exercise
variable.
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Table 5 (Revised). Cox Proportional Hazard Model Comparisons, Including Age and Etiology
of Congestive Heart Failure
Models
Chi-
Square
p
Value
Index
R RR
95% CI
(RR)
PkVO2 lean ,19 ml/kg/min 24.32 ,0.0001 0.067 0.24 0.10–0.58
%PPkVO2 21.53 ,0.0001 0.061 0.97 0.95–0.99
PkVO2 lean ml/kg/min 20.53 0.0001 0.059 0.91 0.85–0.98
PkVO2 ml/kg/min 17.17 0.0007 0.052 0.91 0.84–1.00
PkVO2 ,14 ml/kg/min 16.38 0.0009 0.050 2.22 1.02–4.8
%PPkVO2 ,50 15.65 0.0013 0.048 0.47 0.22–1.03
CI 5 confidence interval; PK 5 peak; PPk 5 predicted peak; RR 5 relative risk; VO2 5 oxygen consumption.
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